Skip to main content

Cardio/Pulmonary

Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

Nov 30, 2021

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.https://t.co/O90HInaS7z https://t.co/MdHVyxfkaW
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2021
ICYMI: Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the #ACR21 annual meeting.https://t.co/5BrxeJBWM2 https://t.co/m8CqyJ1L7A
Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2021
Dr. Janet Pope and Dr. Jeffrey Sparks discuss the importance of lung and several lung-related abstracts presented at the ACR21 annual meeting. https://t.co/s5sl6tdKwP

Dr. John Cush @RheumNow( View Tweet )

Nov 26, 2021
Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush reviews poster #1100 presented at the #ACR21 annual meeting.https://t.co/2YGPHT3AAO https://t.co/lLRKnxB04a
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
Long Term Steroid Use in RA - Matters of the Heart: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstract #1428 presented at the #ACR21 annual meeting.https://t.co/E6RSlPAuRT https://t.co/QBhKD855aH
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
ICYMI: Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitorshttps://t.co/g5FirIK9Af https://t.co/63s7IaKhl7
Dr. John Cush @RheumNow( View Tweet )
Nov 21, 2021
heart.jpg (keep)

Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
heart2.ekg_.red_.jpg

RA: Cardiovascular Risk Stratification and Potential Predictors of Risk

Early cardiovascular disease assessment and management is critical at diagnosis in patients with Rheumatoid Arthritis (RA). Patients with RA have a known increased risk of developing cardiovascular disease (CVD) due to a higher incidence of traditional cardiovascular (CV) risks such as

Read Article
brain.mri2_.jpg

Cognitive Impairment in Patients with Rheumatoid Arthritis

Nov 10, 2021

Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive

Read Article
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
Nov 09, 2021
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
#ACR21 Ab#1939: Tofa CV Outcome (STAR-RA) ▶️Pooled data does not show ⬆️ risk of CVD ▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors Less clear than oral surveillance data, but concerns in those w riskshttps://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc
Nov 09, 2021
STAR-RA, CV risk large insurance datax3 tofa vs TNFi all comers: HR 1.01 (0.83-1.23) one CV RF + any MTX: HR 1.24 (0.90-1.69) prev CVD: HR 1.27 (0.95-1.70) not sig but surely okay to say baseline CV risk + tofa makes me a little nervous? @SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
Nov 09, 2021
Elevated CRP levels (>3) in PsA associated with ⬆️risk of cardiovascular events ⭐️NSAID use significantly REDUCED risk of CV events Abs#1920 #ACR21 @RheumNow https://t.co/gIz9f4SlWo https://t.co/V4uDeO3Iuz
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Another study linking long term GC and CV risk in RA! Medicare data >65yo 130000+ pts 1-year incidence CV ⬆️ as follows: 📍Dose ≤5mg 1.4% 📍Dose 5-10mg 1.7% 📍Dose >10mg 1.9% Not replicated in younger pts (Optum data) #ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW
Aurelie Najm @AurelieRheumo( View Tweet )
Nov 09, 2021
Can we predict who will develop #RA-ILD? Perhaps anti-MAA is the answer! #ACR21 Abs#1916 👉🏼⬆️anti-MAA antibody assoc with incident ILD risk 👉🏼Associations are antigen & isotype dependent 👉🏼Antibody measurement may be useful to risk stratify for RA-ILD @RheumNow https://t.co/nC0OkuWtGU
Mrinalini Dey @DrMiniDey( View Tweet )
Nov 09, 2021
#ACR21 Abs#1915 👉🏼Chronic steroid use in older adults on stable DMARD therapy assoc w/ ⬆️CV risk 👉🏼Risk even present among older adults receiving low dose ≤5mg/day 👉🏼Larger studies needed in younger healthier adults @RheumNow https://t.co/Lsj5YBz7IG
Mrinalini Dey @DrMiniDey( View Tweet )
Nov 09, 2021
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY
Nov 09, 2021
Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abs 1833 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/TxyE4Uqttq https://t.co/Eykxwmcc44
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 09, 2021
Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn
Nov 09, 2021
Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416
Nov 09, 2021
I don't know much about antifibrotics in RA-ILD, but these data emphasise that HRCT pattern matters My simple mind, for any disease: multiple subtypes with different trajectories➡️likely to be differing responses to Rx TRAIL1: pirfenidone in RA-ILD #ACR21 ABSTL10 @RheumNow https://t.co/v7HCO0ZBe1
Nov 09, 2021
×